A clinical trial indicated that apatinib could be used as a second-line or third-line treatment for advanced ESCC.60 A phase II trial in a first-line setting tested apatinib, the PD-1 inhibitor camrelizumab, and chemotherapy in ESCC. The gene discussed is PDCD1; the disease is esophageal squamous cell carcinoma.